^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gallbladder Cancer

    Related cancers:
    2d
    ctDNA guided management of POLE mutant GI malignancies promotes exceptional responses and prolonged survival to immunotherapy. (PubMed, Front Immunol)
    We highlight the utility of a liquid biopsy approach to aid selection of GI cancer patients harbouring rare POLE mutations for immunotherapy, leading to complete metabolic response in addition to radiologic responses and extended survival in all three patients. This study advocates for specialised multi-disciplinary teams performing shared clinical decision making to advance personalised care and improve outcomes of a subset of GI cancer patients with a poor prognosis.
    Journal • MSi-H Biomarker • IO biomarker • Circulating tumor DNA
    |
    MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
    |
    MSI-H/dMMR • POLE mutation
    2d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    2d
    ARTEMIDE-Bil01: Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (clinicaltrials.gov)
    P3, N=757, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • gemcitabine • capecitabine • Teysuno (gimeracil/oteracil/tegafur) • rilvegostomig (AZD2936)
    3d
    AK117-202: A Study of AK112 in Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=154, Completed, Akeso | N=250 --> 154 | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: May 2025 --> Nov 2025 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Yidafan (ivonescimab) • ligufalimab (AK117)
    3d
    A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=135, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Yidafan (ivonescimab)
    5d
    Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression. (PubMed, J Clin Invest)
    In addition, our cohort study showed that high CXCL9 and low LGALS4 in the liver invasion margin demonstrated a favorable prognosis and better responses to anti-PD-1 immunotherapy for patients with gallbladder cancer. Altogether, these findings demonstrate novel cellular and molecular mechanisms underlying liver invasion and offer clinical value for immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • LGALS4 (Galectin 4) • C1QB (Complement C1q B Chain)
    7d
    Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) (clinicaltrials.gov)
    P3, N=810, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> May 2027
    Trial completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    7d
    Diverse Biological Functions of IGF2BPs in Hepatobiliary Cancers and Their Clinical Relevance. (PubMed, Front Biosci (Landmark Ed))
    In hepatobiliary cancers, dysregulated IGF2BP expression is associated with proliferation, metastasis, metabolic adaptation, and immune evasion, underscoring its potential as a biomarker and therapeutic targets. This review provides a comprehensive overview of IGF2BP-mediated regulatory mechanisms and explores their translational potential in precision diagnostics and targeted interventions.
    Review • Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
    7d
    CROCOBIL: Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers (clinicaltrials.gov)
    P2/3, N=160, Not yet recruiting, UNICANCER
    New P2/3 trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • mitazalimab (ADC-1013)
    7d
    Expression of Vascular Endothelial Growth Factor A in Gallbladder Cancer Cells: A Clinicopathological Study. (PubMed, Anticancer Res)
    VEGF expression in GBC was associated with adverse pathological features and poorer survival after curative resection. VEGF immunostaining in resected specimens may provide prognostic value and help identify patients at higher postoperative risk stratification.
    Journal
    |
    VEGFA (Vascular endothelial growth factor A)
    7d
    MOST-CIRCUIT: Combination Immunotherapy in Rare Cancers Under InvesTigation (clinicaltrials.gov)
    P2, N=240, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Trial completion date: Mar 2028 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    8d
    Stage-Dependent Metabolic Responses to Oral Nutritional Supplementation in Cancer Cachexia: A Single-Arm Pilot Study. (PubMed, Nutrients)
    This study showed the feasibility of integrating ONS with multi-omics profiling. Our findings suggest that metabolic alterations might precede clinically detectable changes, potentially providing a rationale for early intervention. Specifically, certain fatty acids were identified as candidate biomarkers that warrant further validation in larger cohorts.
    Journal
    |
    GDF15 (Growth differentiation factor 15)